The University of Chicago Header Logo

Connection

Christopher Rhodes to Hypertension, Pulmonary

Back to Details
This is a "connection" page, showing publications Christopher Rhodes has written about Hypertension, Pulmonary.
Christopher Rhodes
Connection Strength
6.962
Hypertension, Pulmonary
  1. Response by Walters et al to Letter Regarding Article, "SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension". Circulation. 2023 11 28; 148(22):1825-1826.
    View in: PubMed
    Score: 0.662
  2. Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension. Circ Res. 2022 04 29; 130(9):1423-1444.
    View in: PubMed
    Score: 0.593
  3. Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021 04; 57(4).
    View in: PubMed
    Score: 0.551
  4. Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation. 2017 01 31; 135(5):460-475.
    View in: PubMed
    Score: 0.407
  5. Pulmonary hypertension: biomarkers. Handb Exp Pharmacol. 2013; 218:77-103.
    View in: PubMed
    Score: 0.311
  6. Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013 Feb 01; 187(3):294-302.
    View in: PubMed
    Score: 0.309
  7. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 2011 Jul 12; 58(3):300-9.
    View in: PubMed
    Score: 0.281
  8. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J. 2011 Dec; 38(6):1453-60.
    View in: PubMed
    Score: 0.276
  9. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther. 2009 Jan; 121(1):69-88.
    View in: PubMed
    Score: 0.233
  10. Shared and Distinct Genomics of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Embolism. Am J Respir Crit Care Med. 2024 06 15; 209(12):1477-1485.
    View in: PubMed
    Score: 0.172
  11. Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension. Sci Transl Med. 2024 01 10; 16(729):eadd2029.
    View in: PubMed
    Score: 0.167
  12. SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. Circulation. 2023 05 23; 147(21):1606-1621.
    View in: PubMed
    Score: 0.159
  13. Cytokines as prognostic biomarkers in pulmonary arterial hypertension. Eur Respir J. 2023 03; 61(3).
    View in: PubMed
    Score: 0.158
  14. PTPN1 Deficiency Modulates BMPR2 Signaling and Induces Endothelial Dysfunction in Pulmonary Arterial Hypertension. Cells. 2023 01 14; 12(2).
    View in: PubMed
    Score: 0.156
  15. An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis. Commun Biol. 2022 11 07; 5(1):1192.
    View in: PubMed
    Score: 0.154
  16. Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension. J Heart Lung Transplant. 2023 02; 42(2):173-182.
    View in: PubMed
    Score: 0.154
  17. Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life. Nat Commun. 2022 07 27; 13(1):4352.
    View in: PubMed
    Score: 0.151
  18. Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2022 07 01; 206(1):81-93.
    View in: PubMed
    Score: 0.150
  19. Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2022 06 15; 205(12):1449-1460.
    View in: PubMed
    Score: 0.150
  20. A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine. 2021 Jul; 69:103444.
    View in: PubMed
    Score: 0.140
  21. Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. Eur Respir J. 2020 02; 55(2).
    View in: PubMed
    Score: 0.127
  22. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. Am J Respir Crit Care Med. 2020 01 15; 201(2):224-239.
    View in: PubMed
    Score: 0.127
  23. Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. 2019 Jun 01; 20(6):668-676.
    View in: PubMed
    Score: 0.121
  24. The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019 03; 53(3).
    View in: PubMed
    Score: 0.120
  25. Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. Thorax. 2019 04; 74(4):380-389.
    View in: PubMed
    Score: 0.117
  26. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-ß in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2017 08; 37(8):1559-1569.
    View in: PubMed
    Score: 0.106
  27. Pulmonary arterial hypertension - progress in understanding the disease and prioritizing strategies for drug development. J Intern Med. 2017 08; 282(2):129-141.
    View in: PubMed
    Score: 0.105
  28. Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study. Radiology. 2017 05; 283(2):381-390.
    View in: PubMed
    Score: 0.103
  29. Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. Pharmacol Ther. 2016 08; 164:195-203.
    View in: PubMed
    Score: 0.098
  30. In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug. Circulation. 2016 May 03; 133(18):1783-94.
    View in: PubMed
    Score: 0.097
  31. a1-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders. Circ Cardiovasc Genet. 2014 Dec; 7(6):920-9.
    View in: PubMed
    Score: 0.088
  32. miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia. Biochem J. 2014 Aug 15; 462(1):103-12.
    View in: PubMed
    Score: 0.087
  33. Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension. Circulation. 2014 Apr 29; 129(17):1770-80.
    View in: PubMed
    Score: 0.084
  34. BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFß-TAK1-MAPK pathways in PAH. Hum Mol Genet. 2012 Jun 01; 21(11):2548-58.
    View in: PubMed
    Score: 0.073
  35. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart. 2011 Jul; 97(13):1054-60.
    View in: PubMed
    Score: 0.069
  36. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. 2010 May 15; 181(10):1106-13.
    View in: PubMed
    Score: 0.065
  37. Ferroptosis-Mediated Inflammation Promotes Pulmonary Hypertension. Circ Res. 2024 Nov 08; 135(11):1067-1083.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.